Home/ Stocks/ BIIB

Biogen Inc. Common Stock

BIIB XNAS

$183.94 +0.00 (+0.00%) ▲ 15-min delayed

Open

N/A

High

N/A

Low

N/A

Volume

N/A

Market Cap

$26.95B

About Biogen Inc. Common Stock

Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Sector: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Employees: 7.5K Website →

Key Financials

Period	Revenue	Net Income	EPS
TTM 2025	$9.89B	$1.29B	$8.83
FY 2025	$9.89B	$1.29B	$8.83
Q3 2025	$2.53B	$466.50M	$3.18
Q2 2025	$2.65B	$634.80M	$4.33

TickerDaily Coverage

Why Is Vir Biotechnology, Inc. Common Stock (VIR) Stock Up 71.4% Today?

Market News Alex Chen · Feb 24, 2026

Vir Biotechnology (VIR) stock rocketed 71.4% to $7.43, posting one of the day's largest biotech...

View All Coverage →

Get BIIB Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Biogen Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.